Aequus Strengthens Clinical Experience in Stargardt Disease with Pediatric Ophthalmology Expertise

VANCOUVER, British Columbia, Aug. 25, 2021 (GLOBE NEWSWIRE) — Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus”), a specialty pharmaceutical company, is pleased to announce that Dr. Robert K Koenekoop MD, MSc, PhD, FRCS(C), FARVO has joined Aequus as a medical and clinical advisor for hereditary retinal disorders, specifically in support of Aequus’s partnership announced on July 17, 2021 with reVision Therapeutics, Inc. for the product REV-0100, a potential therapy for Stargardt’s disease.

dr. Koenekoop is a pediatric ophthalmologist and director of pediatric ophthalmology and molecular biology of blindness at Montreal Children’s Hospital (MCH). He also holds positions as Professor of Pediatric Surgery, Human Genetics, and Adult Ophthalmology at McGill University and Director of the Retinal Genetics and Therapy Laboratory, and Chief of Pediatric Ophthalmology at the MCH Glen site.

dr. Koenekoop brings more than 25 years of national and international basic and clinical research expertise in ophthalmology, both in children and adults. with dr. Koenekoop’s expert background and medical practice in Canada for hereditary retinal disorders, his valuable insights will advance the REV-0100 program.

“Stargardt macular dystrophy and all other inherited retinal degenerations were considered untreatable by the discoverers of these diseases and many generations of clinical educators and researchers in the field,” said Dr. Koenekoop. “It is very exciting after all these years of patients’ vision deteriorating, that for the first time we are seeing stabilization and even improvements in vision with some of the experimental agents. I am delighted that Aequus has made this decision to collaborate studying the safety and efficacy of REV-0100 in patients”.

REV-0100 is a potential therapy for patients with Stargardt’s disease designed to bind and remove a toxic lipid called lipofuscin. Accumulation of lipofuscin in Stargardt’s disease leads to cell death and retinal degeneration. REV-0100 has the potential to decrease lipofuscin levels in the retina. There are no other known products in development that remove accumulated lipofuscin through this mechanism of action and there is no other approved treatment for Stargardt’s disease.

Story continues

Aequus Pharmaceuticals and Dr. Koenekoop look forward to working closely with reVision Therapeutics to support the development of REV-0100 for Stargardt’s disease.

About Stargardt’s disease
Stargardt’s disease is also called Stargardt macular dystrophy, juvenile macular degeneration, or fundus flavimaculatus. The disease causes progressive damage — or degeneration — of the macula and fovea, an area in the center of the retina responsible for sharp, straight-ahead vision. Stargardt’s disease is one of many, but the most common, cause of genetic disorders that cause juvenile macular degeneration. Experts estimate that 1 in 8-10 thousand people have Stargardt’s disease.

About reVision and REV-0100
reVision Therapeutics, Inc. is an early stage privately held biopharmaceutical company focused on the development and commercialization of innovative therapies for ocular and rare diseases. ReVision’s lead product candidate REV-0100 is being developed as a treatment for Stargardt’s disease and dry age-related macular degeneration (AMD).

About Aequus Pharmaceuticals Inc.
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high-value, differentiated products. Aequus has expanded its sales and marketing efforts to include several commercial products in the field of ophthalmology and transplantation. Aequus plans to build on its commercial platform by launching additional products that are either created internally or come in through an acquisition or license; remain focused on highly specialized therapeutic areas.

Forward-looking statement Disclaimer
This press release may contain forward-looking statements or information under applicable Canadian securities laws that may not be based on historical fact, including, but not limited to, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as factors that we believe are appropriate Forward-looking statements include, but are not limited to, statements regarding: the implementation of our business model and strategic plans; trends in revenue growth in the future; the speed and degree of market acceptance and clinical usefulness d of our products; the company’s expected revenues; and the therapeutic benefits, effectiveness, and safety of our product candidates and third-party products. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based on a number of estimates and assumptions which, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and unforeseen circumstances. Many factors could cause our actual results, performance or performance to differ materially from any future results, performance or performance that may be expressed or implied by such forward-looking statements. In making the forward-looking statements contained in this press release, the company has made several material assumptions, including, but not limited to: the manufacturing capabilities of third-party manufacturers for our product candidates; our ability to promote and market third-party and licensed products; obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully license or sell its current products and to license and develop new products; the assumption that the company’s current good relations with its manufacturer and other third parties will be maintained; the availability of financing on reasonable terms; the company’s ability to attract and retain skilled personnel; competition in the market; the products and technology offered by the Company’s competitors; and the Company’s ability to protect patents and proprietary rights. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set forth herein and under the heading “Risk Factors” in the Company’s April 28, 2020 Annual Information Form, a copy of which is available on Aequus’ profile on the website www.aequus.com. SEDAR website at www.sedar.com, and as otherwise noted from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk not currently known to us, materialize, or if the assumptions underlying these forward-looking statements prove incorrect, actual results could differ materially from those set forth herein. described results. These forward-looking statements are made as of the date of this press release and we do not intend, and assume no obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to place undue reliance on forward-looking statements.

Contact details
Equal Investor Relations
Email: investors@aequuspharma.ca
Phone: 604-336-7906

Comments are closed.